Lung Airflow Ratio and Your Genetics
By the ExomeDNA Research Team
Lung airflow ratio — measured as the FEV1/FVC ratio in standard spirometry — captures how freely air moves through the airways during a forced breath. A ratio closer to 1.0 indicates that airways are open and air moves efficiently; a lower ratio suggests narrowing that slows airflow. Research has identified dozens of genetic loci associated with FEV1/FVC, with genes involved in airway development, inflammation signaling, and nicotinic receptor biology among the strongest supported candidates (Wain et al., 2015; PMID 26634245).
What is lung airflow ratio?
The FEV1/FVC ratio is the core measurement of airway patency captured by standard spirometry testing. FEV1 (forced expiratory volume in one second) measures the volume of air a person can exhale in the first second of a forced breath. FVC (forced vital capacity) measures the total air exhaled during the complete forced breath. The ratio between these two values reflects how easily air moves through the airways: a higher ratio signals open, unobstructed airways, while a lower ratio indicates that air is moving more slowly — a pattern that can arise when airways are narrowed.
A normal adult FEV1/FVC ratio is typically above 0.70 in most clinical guidelines, though reference ranges are adjusted for age, sex, height, and ancestry. As adults age, the ratio naturally declines modestly. Spirometry is one of the primary tools used by clinicians to assess respiratory function and to characterize airway physiology across a range of conditions.
The genetics of FEV1/FVC ratio have been studied through large-scale spirometry-based genome-wide analyses involving tens of thousands of participants from diverse populations. These studies have consistently identified dozens of genomic loci associated with airflow ratio variation, establishing FEV1/FVC as a measurable trait with meaningful heritable contribution that can be investigated through population genetics approaches.
The genetics behind lung airflow ratio
Genome-wide research has identified multiple independent genetic loci contributing to FEV1/FVC variation across populations (Wain et al., 2015; PMID 26634245).
Among the genes with the strongest genetic evidence in this trait, FAM13A — family with sequence similarity 13 member A — is one of the most replicated in lung function genetics. FAM13A has been identified at chromosome 4q22 across multiple spirometry-based GWAS cohorts. Research suggests it participates in signaling pathways active in airway cell biology, and its consistent appearance across independent studies makes it a high-confidence candidate for airflow ratio genetics.
FAM13A: a replicated lung function signal: FAM13A at chromosome 4q22 is among the most consistently replicated genetic signals in FEV1/FVC GWAS studies. Genetic variation near this gene has been associated with differences in measured airflow ratio across large population cohorts in multiple independent datasets, establishing it as a cornerstone of lung function genetics.
HHIP — hedgehog interacting protein — encodes a protein that modulates hedgehog signaling, a developmental pathway critical for normal lung formation and airway branching. Studies have linked HHIP variants to both lung function measures and chronic obstructive pulmonary disease susceptibility, with the gene hypothesized to influence the structural development of airways from early life onward. HHIP's presence in airflow genetics highlights how the architecture of the respiratory system — shaped during development — contributes to adult lung function capacity.
CHRNA5 — cholinergic receptor nicotinic alpha 5 subunit — encodes part of the nicotinic acetylcholine receptor complex. This gene family is well-established in the biology of nicotine response, and CHRNA5 variants have been linked to nicotine dependence as well as lung function outcomes. The intersection here reflects the known influence of smoking history on airway physiology: variants that influence nicotine receptor function may interact with tobacco exposure to shape long-term airflow outcomes across the lifespan.
CHRNA5 and TGFB2: airway biology and signaling: CHRNA5 connects lung genetics to nicotinic receptor biology, highlighting how genetic susceptibility to airway changes may interact with environmental exposures such as tobacco. TGFB2 — transforming growth factor beta 2 — encodes a signaling protein involved in airway remodeling and fibrotic responses, making it a biologically coherent candidate in inflammation-driven airway biology.
TGFB2 (transforming growth factor beta 2) encodes a secreted cytokine in the TGF-beta family. TGF-beta signaling is involved in tissue remodeling, inflammation, and fibrosis — processes with established roles in both normal airway maintenance and disease-associated airway remodeling. GRIP1 (glutamate receptor interacting protein 1) ranks highest among the L2G-prioritized candidates in this analysis; its biological connection to lung airflow continues to be characterized in the literature. MGMT (O-6-methylguanine-DNA methyltransferase) encodes a DNA repair enzyme that appears at an independent chromosomal locus in this analysis, reflecting the polygenic breadth of FEV1/FVC genetics.
What the research says about FEV1/FVC and genetics
Large-scale genome-wide association studies have established FEV1/FVC ratio as a heritable trait with a substantial genetic component. Research in this area has grown considerably, with studies incorporating tens of thousands of participants from diverse populations contributing to the identification of independent genomic loci (Wain et al., 2015; PMID 26634245).
The evidence base for this trait is rated Moderate. This means the genetic associations are well-replicated in population studies, but some uncertainty remains about the precise biological mechanisms through which each variant influences airflow ratio at the individual level. Genetic variants identified in this trait contribute meaningfully to population-level variation in FEV1/FVC but account for only a portion of total heritability — many other genetic and environmental factors contribute to individual airflow outcomes.
A key finding from spirometry genetics is that many of the same loci associated with FEV1/FVC ratio also appear in studies of chronic obstructive pulmonary disease, underscoring the biological connections between continuous airflow measures and respiratory health categories. At the same time, genetic associations reflect population distributions — they do not specify any individual's lung function trajectory over time.
Lifestyle factors — particularly smoking history — remain among the most powerful modifiable influences on FEV1/FVC ratio over a lifetime. Physical activity, respiratory health during childhood, and air quality exposure also contribute meaningfully. Genetic variation provides background context; environmental and behavioral factors shape outcomes within that context.
For more information on how genetic association evidence is evaluated, see ExomeDNA's methodology page (/methodology).
Research base: Moderate.
How lung airflow ratio affects you
Lung airflow ratio is a biomarker of airway patency — how freely air moves through your bronchial passages during a forced breath. Individuals with a genetic tendency toward favorable FEV1/FVC values have, on average, genetic variants associated with more efficient airflow in population studies. This does not mean lung function is predetermined; it means the genetic background for airway biology has measurable population-level variation that interacts with lifestyle and environment across the lifespan.
FEV1/FVC in everyday life: The FEV1/FVC ratio can be measured with a simple spirometer during a routine clinical visit. Results are compared against reference ranges adjusted for age, sex, height, and ancestry. Tracking airflow ratio over time can help detect early shifts in airway function before symptoms develop, providing a window for proactive lifestyle optimization.
Airway physiology responds considerably to lifestyle across the lifespan. Regular aerobic exercise supports respiratory muscle strength and can help maintain favorable airflow over time. Avoiding tobacco exposure — whether active smoking or consistent secondhand smoke — is the single most impactful modifiable factor for preserving favorable airflow ratio across decades. Workplace or environmental air quality exposures are also relevant for individuals in occupational settings with particulate or chemical exposure.
For people with genetic profiles associated with lower airflow capacity tendencies, these lifestyle factors carry the same practical weight — genetics informs context, not determines outcomes.
Working with your airflow profile
Genetic information about lung airflow ratio is most useful in combination with actual spirometry results and clinical assessment. For those with concerns about respiratory function, a spirometry test arranged through a primary care provider offers direct, personalized measurement that genetic data alone cannot provide.
Individuals who have never had spirometry testing, who smoke or have smoked, or who have experienced recurrent respiratory infections may find it particularly worthwhile to discuss lung function monitoring with a clinician. Spirometry is a non-invasive, widely available test that takes minutes and provides objective airway data that can be tracked over time.
The genetic signals in this trait implicate pathways including airway development (HHIP), inflammatory and remodeling signaling (TGFB2), and nicotinic receptor biology (CHRNA5). While these cannot be translated into direct clinical instructions, they highlight that supporting airway health across multiple biological axes — developmental, inflammatory, and behavioral — is a coherent strategy informed by the underlying genetics.
This page is informational only. For health decisions, consult a qualified clinician.
Related traits and genes
Lung airflow ratio is biologically adjacent to several other health traits tracked by ExomeDNA. Respiratory tract health, exercise capacity, and cardiovascular fitness all share physiological pathways with FEV1/FVC. Traits including resting heart rate and exercise endurance connect to the same aerobic systems that intersect with lung function on a daily basis.
CHRNA5, one of the candidate genes in this analysis, also appears in research on nicotine metabolism and smoking behavior — highlighting the gene-environment interaction at the heart of long-term airway health. HHIP's role in hedgehog signaling connects lung development genetics to traits involving structural variation across multiple organ systems.
ExomeDNA's Cardiovascular Health category includes traits covering respiratory and lung function that complement the FEV1/FVC ratio signal reported here, offering a broader view of how cardiovascular and respiratory biology intersect in genetic research.
Frequently asked questions
What does FEV1/FVC ratio actually measure in plain language?
It measures what fraction of your total forced-breath air capacity you can exhale in the first second. If your full forced breath contains 4 liters of air and you exhale 3 liters in the first second, your ratio is 0.75. A higher fraction generally indicates more open airways. Reference ranges in adults are adjusted for age, sex, height, and ancestry — so interpretation always requires comparison against appropriate population norms.
Does a genetic tendency toward lower airflow ratio mean I will have breathing problems?
No. Genetic variants associated with lower airflow ratio in population studies reflect average tendencies across large groups — not individual predictions. Many factors including lifestyle, physical activity, and environmental exposures influence individual respiratory function. Genetics provides context about background likelihood in populations, not a personal prognosis for any specific person.
Why does CHRNA5 appear in lung airflow genetics?
CHRNA5 encodes part of the nicotinic acetylcholine receptor. This receptor family is directly involved in nicotine response. Research has linked CHRNA5 variation to both smoking behavior and lung function outcomes, making it a biologically coherent candidate for FEV1/FVC associations, particularly in populations with varied smoking histories where nicotinic receptor biology intersects with airway physiology.
Can lung airflow ratio improve over time?
Yes. While genetics sets background context, airflow ratio responds to behavioral and environmental factors. Avoiding smoking, maintaining aerobic fitness, and minimizing exposure to particulate air pollution support better airflow outcomes over the long term. Research shows that adults who quit smoking demonstrate measurable improvement in airflow capacity relative to those who continue.
How is this different from a clinical assessment for asthma or COPD?
This genetic profile is associated with population-level variation in FEV1/FVC ratio — a continuous measure of airway patency. Asthma and COPD are clinical characterizations involving symptoms, spirometry patterns over time, response to bronchodilators, and clinical history, all interpreted by a qualified clinician. Genetic population-level research informs background susceptibility context; clinical evaluation involves entirely different evidence and methods.
References
Wain et al. (2015). Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease. PMID 26634245.
Data sources: Genetic variant associations from GWAS Catalog; gene-to-trait mapping from population-level GWAS data; ClinVar pathogenicity annotations from NCBI ClinVar; gene functional annotations from NCBI Gene.
Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder. Reviewed by the ExomeDNA Science Team.
This does not constitute a clinical evaluation, treatment recommendation, or clinical genetic test. ExomeDNA's genetic reports are for wellness and educational purposes only.